Scholar Rock Holding (SRRK) Total Debt (2017 - 2026)
Scholar Rock Holding's quarterly Total Debt came in at $196.6 million in Q1 2026, up 295.28% year-on-year from $49.7 million in Q1 2025, and up 97.19% quarter-over-quarter from $99.7 million in Q4 2025.
Scholar Rock Holding has reported Total Debt for 10 years, with the latest figure at $196.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Debt rose 295.28% year-over-year to $196.6 million; the trailing twelve-month figure through Mar 2026 stood at $196.6 million (up 295.28% YoY), and the FY2025 full-year result was $99.7 million, up 98.84% from the prior year.
- Total Debt for Q1 2026 stood at $196.6 million, up from $99.7 million in the prior quarter.
- The five-year high for Total Debt was $196.6 million in Q1 2026, with the low at $49.7 million in Q1 2025.
- Average Total Debt over 5 years is $64.5 million, with a median of $50.1 million recorded in 2024.
- Year-over-year, Total Debt retreated 1.21% in 2023 and soared 295.28% in 2026.
- Tracing SRRK's Total Debt over 5 years: stood at $49.7 million in 2022, then advanced by 0.55% to $50.0 million in 2023, then gained by 0.26% to $50.1 million in 2024, then surged by 98.84% to $99.7 million in 2025, then jumped by 97.19% to $196.6 million in 2026.
- The last three Total Debt figures came in at $196.6 million (Q1 2026), $99.7 million (Q4 2025), and $99.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 196.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 196.61 Mn |
| Dec 31, 2025 | 99.71 Mn |
| Sep 30, 2025 | 99.61 Mn |
| Jun 30, 2025 | 49.76 Mn |
| Mar 31, 2025 | 49.74 Mn |
| Dec 31, 2024 | 50.15 Mn |
| Sep 30, 2024 | 50.10 Mn |
| Jun 30, 2024 | 50.07 Mn |
| Mar 31, 2024 | 50.10 Mn |
| Dec 31, 2023 | 50.02 Mn |
| Sep 30, 2023 | 49.96 Mn |
| Jun 30, 2023 | 49.90 Mn |
| Mar 31, 2023 | 49.83 Mn |
| Dec 31, 2022 | 49.74 Mn |
| Sep 30, 2022 | 50.57 Mn |
| Jun 30, 2022 | 50.39 Mn |
| Mar 31, 2022 | 50.20 Mn |
| Dec 31, 2021 | 50.00 Mn |
| Sep 30, 2021 | 24.93 Mn |
| Jun 30, 2021 | 24.85 Mn |
| Mar 31, 2021 | 24.76 Mn |
| Dec 31, 2020 | 24.68 Mn |
| Sep 30, 2020 | 6,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | 14,000.00 |
| Dec 31, 2019 | 9,000.00 |
| Sep 30, 2019 | 13,000.00 |
| Jun 30, 2019 | 17,000.00 |
| Mar 31, 2019 | 290,000.00 |
| Dec 31, 2018 | 448,000.00 |
| Sep 30, 2018 | 578,000.00 |
| Jun 30, 2018 | 731,000.00 |
| Dec 31, 2017 | 1.04 Mn |